Other NIH Programs for Translational Neuroscience that Support Biologics

Funding for Assay Development and Screening

IGNITE: Assay Development and Neurotherapeutic Agent Identification

  • Support: 3-year R61/R33 to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential neurotherapeutic agents
  • Participating Institutes: NINDS, NCCIH
  • To apply: PAR-21-124

​​​​​​​​​​​​​​​​​​​​​

Funding for Preclinical Proof-of-Concept

Drug Discovery for Nervous System Disorders

IGNITE: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies

  • Support: 3-year R61/R33 to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development
  • Participating Institute: NINDS
  • To apply: PAR-21-122

 

Funding for Translational Model Development

IGNITE: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery

  • Support: 3- year R61/R33 to support development and validation of animal models and ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder
  • Participating Institute: NINDS
  • To apply: PAR-21-123

 

Funding for Preclinical/Clinical Development

National Cooperative Drug Discovery/Development Groups (NCDDG)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
  • Participating Institute: NIAAA
  • To apply: PAR-18-580 (UT2 - Clinical Trial Optional)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
  • Participating Institute: NIAAA
  • To apply: PAR-18-578 (U44 - Clinical Trial Optional)

Strategic Alliances for Medications Development to Treat Substance-Use Disorders

  • Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds
  • Participating Institute: NIDA
  • To apply: PAR-19-318 (R01)

Grand Opportunities in Medications Development for Substance-Use Disorders

  • Support: Up to 3 years of funding, milestone-driven, up to $5M per year
  • Participating Institute: NIDA
  • To apply: PAR-19-327 (U01)

Alzheimer's Drug-Development Program

  • Support: Up to 5 years of funding, milestone-driven, up to $1M per year
  • Participating Institute: NIA
  • To apply: PAR-18-820 (U01)

 

Services

Services for Pharmacology

Epilepsy Therapy Screening Program (ETSP)

  • Support: Screens compounds in animal seizure models
  • To apply: Contact Brian Klein, Ph.D.

Addiction Treatment Discovery Program (ATDP)

  • Support: Screens compounds in animal models of addiction
  • To apply: Contact David White, Ph.D., (301) 443-8889

Services for Toxicology

Bridging Interventional Development Gaps (BrIDGs)

NIDA Toxicology Program

  • Support: Provides IND-directed toxicology services for substance abuse indications.
  • To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475

Regulatory Affairs Assistance for Medications Development

  • Support: Provides consultation and advice on regulatory requirements
  • Participating Institute: NIDA
  • To apply: Contact Robert Walsh, R.A.C.

BPN-Biologics Staff

Program Director
Dr. Ann-Marie Broome

Program Specialists
Dr. Julia Bachman

 

Project Managers

Dr. Chris Boshoff
Dr. Mario Skiadopoulos

Operations Coordinator
Ms. Natasha Davis

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 06/2024